Comprehensive Overview

The Group is a new clinical drug developer in China that focuses on independent research and development of potentially first-of-its-kind and best-in-class cancer drugs and drugs for other androgen receptor-related (or AR-related) diseases.

The group's main drug under development, pucluramide, is a potentially best-in-class drug. Phase III clinical trials for metastatic castration-resistant prostate cancer (or mCRPC) are underway in China, phase II clinical trials and clinical trials for breast cancer are underway in the US.

Currently, the group has developed five drugs under development and has obtained approval to commence clinical trials in China, the US and/or Taiwan. These clinical drugs under development include procluramide, forretane, ALK-1, ditocetil, and HedgeHog/Smo inhibitors.

Risk Factors

The Group is a biomedical company that has lost track records and has no revenue. The Group can anticipate future financial prospects depending on whether the Group can successfully commercialize the drugs it is developing. If the Group fails to commercialize any of the Group's active drugs or otherwise realize or maintain profits, investors may lose all or a significant portion of their investment.